Intrauterine Insemination In HIV-Discordant Couples

Stopped early · Not applicable

Conditions studied: HIV-1, Fertility, Infertility

In brief

This study aims to assess the feasibility of a novel standard of care technique for intrauterine insemination (IUI) in HIV-discordant couples in the United States. This study will involve couples in which the male partner is HIV positive, but the female partner is negative. The investigators will institute a protocol similar to those used presently throughout Europe with good success. To date, no HIV seroconversions have occurred in over 4000 inseminations performed in HIV serodiscordant couples. All male subjects will be on stable HAART, and have undetectable serum viral loads prior to insemination. Semen samples will be subjected to a stringent sperm wash procedure and screened for HIV RNA. Female subjects will be followed post-insemination for seroconversion and pregnancy. Infants will be followed for seroconversion at birth through 4 months of age.

Key facts

Study ID

NCT01173276

Run by

Boston Medical Center

People needed

10

Starts

2009-09-01

Expected to finish

2013-10-01

Last updated by the study team

2016-02-22

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Couples with HIV discordance with an HIV seronegative female partner and HIV seropositive male partner
• Men must be HIV positive with an undetectable viral load (<75 copies/ml)
• Men must be clinical stable on antiretroviral therapy for 6 months
• Men must have a CD4 count > 250 at screening
• Men must be between 18-50 years of age
• Men must have a baseline test sperm preparation demonstrating at least 10 million motile sperm per sample
• Men must have a letter of medical clearance specific for this procedure from primary care physician stating that subject is in good health and psychologically stable
• Men must be willing to have constituent follow-up of HIV care throughout study participation
• Women must have an HIV-1/HIV-2 negative serology at screening
• Women must be between 18-40 years of age
• Women must have a body mass index (BMI) less than 30
• Women must be a non-smoker
• Women must be ovulatory (as determined by LH tracking)
• Women must have normal uterine cavity with at least one documented patent fallopian tube (as determined by hysterosalpingogram)
• Women must have adequate day 3 ovarian reserves: FSH,12 mlU/ml and estradiol<80pg/ml
• Women must have no evidence of active urogenital infection at screening
• Women must have a normal PAP smear and GC/Chlamydia at screening
• Women must have a letter of medical clearance specific to this procedure from subject's primary care physician stating that subject is in good health and psychological stable.

You may not qualify if…

• Subjects with untreated sexually transmitted diseases (syphilis, GC, CT)
• Men with detectable viral load (>75) at screening
• Subjects with any condition (including, but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subject's safety or adherence to the protocol
• Subjects with any uncontrollable medical or psychiatric condition that,in the opinion of the investigator, cannot be adequately stabilized and could be considered a contraindication to participation

Where it is running

• Boston Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.